United States · Investor

Foresite Capital

Last cheque observed Sep 2026; 121 cheques on record.

Deploying nowNew fund $85M, Oct 2023Private equityWebsite unconfirmed

SeedSeries ASeries BHealthcareWellnessLongevity

Deploying now
79%of best year27cheques in 12 months, 121 on record
Since the last cheque60days00hrs00min00sec
Median round$90MCheque size, as they say$100K – $5.0MRounds led3 of 121Sole investor4 roundsExits2 from the portfolioMostly inUnited States, 92%
Pitch Foresite Capital

Foresite Capital highlights

  1. 01

    27 cheques in the last 12 months

  2. 02

    Mostly Series B and Series C: 64% of its rounds

  3. 03

    Sole investor in 4 rounds, median $78M

  4. 04

    2 exits from the portfolio

What they do

Type
Private equity (from a list, unverified)
Cheque size
$100K – $5.0M as they say
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
HealthcareWellnessLongevity
Based in
Larkspur, United States
Cold pitches
Not stated

A website was listed for this organisation, but we could not confirm it belongs to the firm that wrote these cheques. Either the site never mentions them, or it turned out to be a different company sharing the name. We show neither it nor anything read from it. Tell us the right one.

The record

Every round we can evidence, newest first121 appearances

  1. 2026

    22 rounds

  2. Sept
    Intellia TherapeuticsDebt · US$400MWith 3 others
  3. Sept
    Tempest TherapeuticsUS$2.5MWith 4 others
  4. Sept
    Thyme CareSeries E · US · Echo Health Ventures$125MWith 12 others
  5. Sept
    Korsana BiosciencesUS$380MWith 3 others
  6. Aug
    Khartis TherapeuticsSeries B · US · Ventureburn$50MWith 5 others
  7. Jun
    StepfulSeries C · US · Ventureburn$55MWith 7 others
  8. Jun
    ALX OncologyDebt · US$10MWith 4 others
  9. May
    CerevanceSeries C · US$20MWith 1 other
  10. May
    Relay TherapeuticsUS$275MWith 3 others
  11. May
    PharvarisCH$132MWith 4 others
  12. Apr
    GH ResearchIE$118MWith 4 others
  13. Apr
    ImageneBioUS$30MWith 4 others
  14. Mar
    Pinnacle MedicinesSeries B · US$89MWith 3 others
  15. Mar
    Seaport TherapeuticsGrant · US$15MWith 2 others
  16. Mar
  17. Feb
    Midi HealthSeries D · US$100MWith 4 others
  18. Feb
    Third Arc BioSeries A · US$52MWith 4 others
  19. Feb
    Beam TherapeuticsDebt · US$100MWith 5 others
  20. Feb
    Slate MedicinesSeries A · US$130MWith 2 others
  21. Jan
    VaxcyteUS$633MWith 3 others
  22. Jan
    bit.bioSeries C$50MWith 5 others
  23. Jan
    AlumisUS$345MWith 6 others
  24. 2025

    24 rounds

  25. Dec
    Fulcrum TherapeuticsUS$175MWith 4 others
  26. Dec
    Aeovian PharmaceuticalsSeries B · US$55MWith 2 others
  27. Dec
    MyomeVenture · USUndisclosedWith 4 others
  28. Dec
    Wave Life SciencesUS$350MWith 4 others
  29. Nov
    InvivydUS$125MWith 5 others
  30. Oct
    AtaiBeckleyDE$150MWith 4 others
  31. Oct
    Tango TherapeuticsUS$197MWith 3 others
  32. Oct
    Nurix TherapeuticsUS$250MWith 5 others
  33. Oct
    Rapt TherapeuticsUS$250MWith 6 others
  34. Oct
    Arcus BiosciencesUS$250MWith 3 others
  35. Oct
    IndomoSeed · US$25MWith 1 other
  36. Sept
    Korsana BiosciencesSeries A · US$150MWith 5 others
  37. Sept
    Avenzo TherapeuticsSeries B · US$60MWith 5 others
  38. Sept
    Thyme CareSeries D · US$97MWith 3 others
  39. Aug
    MirvieVenture · US$24MWith 4 others
  40. Aug
    Kriya TherapeuticsSeries D · US$321MWith 2 others
  41. Jul
    Quantum SIUS$50MWith 2 others
  42. May
    ORIC PharmaceuticalsUS$125MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration4 named

ABAmelia Buckley StojChief Compliance Officer and Assistant General CounseliForm ADV
DSDana Shonfeld TananbaumTrusteeiForm ADV
DDDennis Drew RyanChief Financial Officer and Managing DirectoriForm ADV
JBJames Bruce TananbaumManaging Member of the General PartneriFiling they signed

We also hold 25 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$3.2Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
Foresite Capital Management, LLC
SEC number
CRD 162823

Funds on its Form ADV

9 private funds, $3.5B in gross assets · filed Mar 2024

  1. Foresite Capital Fund IV, L.P.Venture177 investors$1.2B
  2. Foresite Capital Fund V, L.P.Venture405 investors$909M
  3. Foresite Capital Fund VI L.P.Venture314 investors$723M
  4. Foresite Capital Opportunity Fund V, L.P.Venture405 investors$233M
  5. Foresite Capital Fund III, L.P.Venture163 investors$175M
  6. Foresite Labs Fund I, L.P.Venture97 investors$154M
  7. Foresite Capital Fund II, L.P.Venture139 investors$43M
  8. Foresite Capital VI-A, LLCVenture18 investors$20M
  9. Foresite Capital Fund I, L.P.Venture70 investors$18M

What they claim to have backed

From their own portfolio page (on their website)

0 of 1 we have independently watched raise

GOODLAB

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Exits from the portfolio

Companies it backed that were later bought or listed2 in all

SequentaBought by Adaptive BiotechnologiesUndisclosedJan 2015
Karyopharm TherapeuticsListedUndisclosedNov 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Foresite Capital. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Foresite Capital put money into.

Mentioned on podcasts

Episodes that name Foresite Capital in their description, not their title.

Quick answers about Foresite Capital

What does Foresite Capital invest in?

Foresite Capital invests most often at Series B and Series C (64% of the rounds on record), in sectors such as Healthcare, Wellness and Longevity.

How active is Foresite Capital?

121 investments on record, 27 of them in the last 12 months, and it led 3. The most recent was in Sept 2026.

What has Foresite Capital invested in recently?

Its most recent investments on record: Intellia Therapeutics (Debt, Sept 2026), Tempest Therapeutics (Undisclosed round, Sept 2026) and Thyme Care (Series E, Sept 2026).

How big are Foresite Capital's cheques?

The median round it joins is $90M. It says it writes cheques of $100K to $5.0M.

Does Foresite Capital lead rounds?

Sometimes: it led 3 of its 121 investments on record (2%).

Where does Foresite Capital invest?

Most of the companies it backs are in the United States (92%).

Is Foresite Capital investing now?

Yes: it is actively investing, with 27 investments in the last 12 months.

Who does Foresite Capital invest alongside?

Most often RA Capital Management (26 rounds together), OrbiMed (22 rounds together) and Cormorant Asset Management (17 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it